The most effective FDA-approved weight loss medication. Lose up to 25% of your body weight with dual GLP-1/GIP action. Medical supervision at our Sandy and Layton clinics.
Tirzepatide represents the next generation of weight loss medication. Unlike semaglutide which only activates GLP-1 receptors, tirzepatide is a "twincretin"—it activates both GLP-1 and GIP receptors for enhanced metabolic effects.
This dual action makes tirzepatide the most effective FDA-approved medication for weight loss, producing an average of 20-25% body weight loss in clinical trials—about 5% more than semaglutide.
SURMOUNT-1 trial showed 22.5% average weight loss at the highest dose—more than any other FDA-approved medication.
95% of patients achieved clinically significant weight loss of at least 5% of body weight.
63% of patients lost 20% or more of their body weight at the maximum dose.
The average patient lost approximately 52 pounds over the 72-week trial period.
Both are excellent medications, but tirzepatide offers advantages for patients seeking maximum weight loss:
We'll help you choose the best medication for your specific goals and situation.
Free evaluation to assess your health, weight loss goals, and determine if tirzepatide is right for you.
Begin with 2.5mg weekly for 4 weeks to allow your body to adjust and minimize side effects.
Gradually increase dose every 4 weeks (5mg → 7.5mg → 10mg → 12.5mg → 15mg) based on tolerance and response.
Regular check-ins, nutritional guidance, and protocol adjustments to maximize your results.
FDA-approved for type 2 diabetes. Uses tirzepatide to improve blood sugar control, with weight loss as a significant secondary benefit. Often prescribed off-label for weight loss.
FDA-approved specifically for chronic weight management in 2023. Same medication as Mounjaro but indicated for obesity treatment. The formulations are identical.
The medication is identical. Choice often depends on insurance coverage and prescribing indication. We help navigate these options to find the most accessible and affordable path for you.
Tirzepatide is a revolutionary dual-action medication that activates both GLP-1 and GIP receptors. Brand names include Mounjaro (for diabetes) and Zepbound (for weight loss). It's the most effective FDA-approved weight loss medication, helping patients lose up to 25% of their body weight.
Clinical trials show patients lose an average of 20-25% of their body weight with tirzepatide—significantly more than semaglutide. Some patients lose over 50 pounds. Results vary based on starting weight, dose, diet, exercise, and individual response.
Clinical studies show tirzepatide produces greater weight loss than semaglutide (20-25% vs 15-20%). The dual GLP-1/GIP mechanism provides additional metabolic benefits. However, both are highly effective, and the best choice depends on individual factors and tolerability.
Common side effects include nausea, vomiting, diarrhea, constipation, and stomach pain, especially when starting or increasing doses. These typically improve over time. Our gradual titration approach helps minimize side effects.
Tirzepatide is given as a once-weekly subcutaneous injection. Starting dose is 2.5mg, gradually increasing every 4 weeks to the target dose (up to 15mg). We teach you how to self-administer at home with simple injector pens.
Zepbound is FDA-approved for adults with BMI ≥30 (obesity) or BMI ≥27 with a weight-related condition. It's not recommended for those with personal or family history of medullary thyroid cancer, MEN 2 syndrome, or history of pancreatitis.
Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved specifically for chronic weight management. The formulations are identical, but indications and insurance coverage may differ.
Schedule your FREE consultation today to learn if tirzepatide is right for you. No obligation, personalized guidance.
Financing available through LiteCredit